Definitive Healthcare Corp. (DH)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-09-29. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 31/100 (MEDIUM), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 5.01% of float, squeeze risk: LOW
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Definitive Healthcare Joins the Network Advertising Initiative to Strengthen Data Privacy Compliance in Healthcare Marketing
- Definitive Healthcare Shares Rise 13% After Advent International Submits $1.02-Per-Share Proposal
- Definitive Healthcare Appoints Clay Ritchey as CEO
- Definitive Healthcare (DH) Q2 2026 Earnings Call
- Definitive Healthcare Corp (DH) (Q2 2026) Earnings Call Highlights: AI Platform Launch and ...
- Definitive Healthcare Q2 Earnings Call Highlights
- Definitive Healthcare Announces Timing of Its Second Quarter 2026 Financial Results Conference Call and Webcast
- Special Committee of Definitive Healthcare Board Confirms Receipt of Going-Private Proposal from Advent International
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Definitive Healthcare Corp..
Full DH Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.